Education
About Us
Working with TipRanks
Follow Us
Syros Pharmaceuticals (SYRS)
OTHER OTC:SYRS
| Dec 23 | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 9.94M | $ 14.88M | $ 23.49M | $ 15.09M | $ 1.98M |
| Gross Profit | $ 7.68M | $ 11.91M | $ 23.49M | $ 15.09M | $ 1.98M |
| Operating Income | $ -128.99M | $ -135.87M | $ -99.42M | $ -82.30M | $ -77.74M |
| EBITDA | $ -157.19M | $ -87.55M | $ -79.63M | $ -79.21M | $ -72.72M |
| Net Income | $ -164.57M | $ -94.65M | $ -86.56M | $ -84.04M | $ -75.44M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 139.53M | $ 202.30M | $ 130.37M | $ 173.98M | $ 91.42M |
| Total Assets | $ 168.17M | $ 244.49M | $ 182.94M | $ 213.25M | $ 149.98M |
| Total Debt | $ 62.08M | $ 63.57M | $ 65.19M | $ 66.21M | $ 25.92M |
| Net Debt | $ -77.45M | $ -103.90M | $ -27.11M | $ -107.77M | $ -15.52M |
| Total Liabilities | $ 151.51M | $ 116.75M | $ 97.72M | $ 122.70M | $ 70.79M |
| Stockholders' Equity | $ 16.66M | $ 127.74M | $ 85.22M | $ 90.55M | $ 79.18M |
| Cash Flow | |||||
| Free Cash Flow | $ -109.98M | $ -124.31M | $ -100.78M | $ -60.70M | $ -72.89M |
| Operating Cash Flow | $ -109.71M | $ -123.06M | $ -99.54M | $ -57.36M | $ -60.25M |
| Investing Cash Flow | $ 37.34M | $ 67.19M | $ -52.65M | $ 46.66M | $ -11.73M |
| Financing Cash Flow | $ 43.46M | $ 131.04M | $ 70.51M | $ 142.95M | $ 65.99M |
Syros Pharmaceuticals Forecast EPS vs Actual EPS
Currently, no data available
Please return soon. This page is being updated.